News

DFW Capital Partners announced today that it has completed the sale of its portfolio company, Fleetwash Holdings, Inc., to an affiliate of ACON Investments. The sale represents the fifth sale or major liquidity event for the firm’s 2012 vintage fund, DFW Capital Partners IV, LP.

More

DFW Capital Partners (“DFW”) announced today that it has completed a growth investment in Restoration + Recovery, a leading provider of post-construction stormwater management services, including inspection, maintenance, repair, consulting services and emergency response, based in Durham, NC.

More

DFW Capital Partners (“DFW”) is pleased to announce that it has completed the sale of its portfolio company, Evolution Research Group (“ERG”), to Linden Capital Partners.

More

DFW Capital Partners announced today that its portfolio company, Sebela Pharmaceuticals, has completed the acquisition of Braintree Laboratories Inc.

More

DFW announced today that it has completed an investment in ReSource Pro Holdings, LLC 

More

DFW Capital Partners (“DFW”) is pleased to announce that it recently completed a strategic investment in INSIGHT2PROFIT. INSIGHT2PROFIT is a fast growing technology-enabled service company focused on delivering sustainable revenue and EBITDA growth through implementation and management of pricing and profit strategies. INSIGHT2PROFIT has locations in Cleveland, Ohio and Chicago, Illinois.

More

DFW Capital Partners is pleased to announce that its existing portfolio company, Evolution Research Group (“ERG”), has acquired Brain Matters Research (“BMR”), of Delray Beach, Florida.

More

DFW Capital Partners announced today that it has completed the sale of its portfolio company, Covenant Surgical Partners, Inc. (“Covenant”), to an affiliate of private equity firm Kohlberg, Kravis & Roberts.

More

DFW Capital Partners is pleased to announce that its existing portfolio company, Saol Therapeutics, has acquired to acquire three marketed hyperimmune products, WinRho® SDF (Rh0(D) Immune Globulin Intravenous (Human)), HepGam B® (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG® (Varicella Zoster Immune Globulin (Human)) from Aptevo Therapeutics Inc. (Nasdaq: APVO). The deal includes both upfront and milestone payments.

More

DFW Capital Partners is pleased to announce that its existing portfolio company, Evolution Research Group (“ERG”), has acquired Endeavor Clinical Trials (“ECT”), of San Antonio, Texas. ECT has over 20 years of experience conducting over 185 clinical trials, specializing in post-operative pain, neuropathic pain, podiatry, and vaccine research, among others

More